Novavax reports $68 million third quarter 2026 revenue
It raises full-year 2026 adjusted total revenue guidance to $400 million at the midpoint and earned a $125 million Sanofi milestone.
See the latest news and media coverage for Novavax. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing vaccines
novavax.comLast updated
In short: Novavax raised its 2026 revenue outlook after reporting $68 million in third-quarter revenue.
It raises full-year 2026 adjusted total revenue guidance to $400 million at the midpoint and earned a $125 million Sanofi milestone.
Sanofi leads expansion across North America and Europe this season. Takeda maintains strong sales in Japan under revised terms.
The company highlights continued progress on its corporate growth strategy and hosts a live earnings call at 8:30 a.m. ET.
Total revenue declined 76% to $57 million, net loss $53 million. Raised full-year revenue guidance and reduced expense guidance. Sanofi partnership and C. difficile program highlighted.
Novavax (NVAX) shares fell more than 7% in early Thursday trading after the company reported lower Q3 revenue. The company reported a Q3 net loss...
Novavax (NVAX) stock rises as the company raises its 2026 revenue outlook after a Q3 beat driven by stronger vaccine sales and lower costs. Read...
Vaccine maker Novavax raised its annual revenue forecast above Wall Street expectations on Thursday...
Novavax ( ) has provided an announcement. On October 28, 2026, Sanofi Pasteur dosed the fifth patient in its Phase 3 influenza-COVID-19 combination vaccine trial...
Track Novavax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Novavax and other trending companies.